STOCK TITAN
  1. Home
  2. News
  3. MEIP

MEI Pharma, Inc. - MEIP STOCK NEWS

Welcome to our dedicated page for MEI Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on MEI Pharma stock.

MEI Pharma, Inc. (NASDAQ: MEIP), based in San Diego, is an oncology-focused biotechnology company dedicated to the clinical development of innovative cancer therapies. The company's mission is to improve the quality of life and outcomes for cancer patients through the development of novel treatments.

Core Business and Drug Candidates:

  • Pracinostat: MEI Pharma's lead drug candidate, Pracinostat, is an oral histone deacetylase (HDAC) inhibitor. It has received breakthrough therapy designation from the FDA when used in combination with azacitidine for treating patients with newly diagnosed acute myeloid leukemia (AML) who are aged 75 or above, or those unfit for intensive chemotherapy.
  • ME-401 (formerly PWT143): A next-generation oral phosphatidylinositide 3-kinase delta (PI3K delta) inhibitor being developed for patients with recurrent chronic lymphocytic leukemia (CLL) or follicular non-Hodgkin's lymphoma (NHL).
  • ME-344: This isoflavone-based mitochondrial inhibitor is being explored for the treatment of HER2-negative breast cancer, demonstrating MEI Pharma's commitment to addressing unmet needs in oncology.

Recent Achievements and Partnerships: MEI Pharma has made significant strides in its clinical programs. The breakthrough therapy designation for Pracinostat underscores its potential impact in the treatment landscape of AML. In addition, strategic collaborations with leading research institutions and oncology experts bolster the company's development capabilities and market positioning.

Financial Condition: MEI Pharma continues to focus on advancing its clinical pipeline while maintaining a prudent financial strategy. The company’s investment in cutting-edge research and clinical trials is supported by strategic funding initiatives, ensuring sustained progress in its mission to combat cancer.

Current Projects: The clinical development of Pracinostat, ME-401, and ME-344 remains at the forefront of MEI Pharma’s efforts. Ongoing clinical trials and research are expected to provide valuable data, guiding future regulatory submissions and potential market approvals.

With a robust pipeline and a clear focus on innovative cancer therapies, MEI Pharma, Inc. stands as a significant player in the oncology sector. For more information, please visit www.meipharma.com.

News

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Rhea-AI Summary
MEI Pharma reports fiscal year 2023 results, expects data readouts from ongoing clinical studies in 2024. ME-344 in combination with Avastin in colorectal cancer and voruciclib in combination with Venclexta in acute myeloid leukemia. Positive data would support further development. MEI had $100.7 million in cash, cash equivalents, and short-term investments with no debt as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
earnings
-
News

MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

Rhea-AI Summary
MEI Pharma to release fiscal year end financial results on September 26, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.92%
Tags
conferences earnings
-
News

MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

Rhea-AI Summary
MEI Pharma, Inc. responds to director nomination, highlights progress in clinical development and commitment to stockholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
News

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Rhea-AI Summary
MEI Pharma has announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab in patients with previously treated metastatic colorectal cancer. ME-344 is a mitochondrial inhibitor targeting energy production, while bevacizumab is a VEGF inhibitor. The study aims to evaluate the combination's potential to inhibit energy production in tumor cells and induce an antitumor effect. Safety and efficacy data from the first cohort of patients are expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
clinical trial
-
News

MEI Pharma Announces Results of Special Meeting of Stockholders

Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) announced the termination of the merger agreement with Infinity Pharmaceuticals, Inc. due to not obtaining the necessary stockholder votes. The certified results showed that 47.86% voted in favor, and 51.44% against. MEI remains focused on its current development pipeline, including Voruciclib and ME-344, with clinical data expected by year-end. MEI's clinical-stage development programs have the potential to improve patient outcomes in cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) reminds shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) in connection with the special meeting on July 23, 2023. Independent leading proxy advisory firms ISS and Glass Lewis recommend shareholders vote FOR the transaction. The combined company is well capitalized to advance three differentiated clinical-stage therapeutic development pipelines, creating opportunities for shareholders to benefit from near-term value creation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
News

MEI Pharma Responds to Anson and Cable Car

Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP): Response to Consent Solicitation by Anson Advisors Inc. and Cable Car Capital LLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
-
News

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

Rhea-AI Summary
MEI Pharma encourages shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, creating a combined company with a diversified pipeline of three clinical-stage development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
-
News

MEI Pharma Postpones Special Meeting of Shareholders

Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) has postponed its special meeting with Infinity Pharmaceuticals, Inc. to July 23, 2023. Leading proxy advisory firms ISS and Glass Lewis recommend MEI shareholders vote for the transaction. MEI shareholders have an opportunity to participate in a well-capitalized combined company with a diversified pipeline of three clinical-stage development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.22%
Tags
none
News

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) reminds shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) in connection with the upcoming special meeting on July 14, 2023. Leading proxy advisory firms, ISS and Glass Lewis, recommend MEI shareholders vote FOR the Infinity transaction, recognizing its strategic benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
acquisition

FAQ

What is the current stock price of MEI Pharma (MEIP)?

The current stock price of MEI Pharma (MEIP) is $2.5 as of December 20, 2024.

What is the market cap of MEI Pharma (MEIP)?

The market cap of MEI Pharma (MEIP) is approximately 16.3M.

What is MEI Pharma, Inc.?

MEI Pharma is a San Diego-based biotechnology company focused on developing innovative cancer therapies.

What is Pracinostat?

Pracinostat is MEI Pharma's lead drug candidate, an oral HDAC inhibitor for treating acute myeloid leukemia (AML) in certain patients.

What other drug candidates does MEI Pharma have?

MEI Pharma's pipeline includes ME-401, a PI3K delta inhibitor, and ME-344, a mitochondrial inhibitor.

What recent achievements has MEI Pharma made?

Pracinostat received breakthrough therapy designation from the FDA for certain AML patients.

What partnerships does MEI Pharma have?

MEI Pharma collaborates with leading research institutions and oncology experts to advance its clinical programs.

How is MEI Pharma financially supported?

MEI Pharma maintains a prudent financial strategy, supported by strategic funding initiatives for its research and clinical trials.

Where can I find more information about MEI Pharma?

More information can be found on their official website: www.meipharma.com.

What are the main focuses of MEI Pharma's current projects?

MEI Pharma is focused on the clinical development of Pracinostat, ME-401, and ME-344 through ongoing trials and research.

Where is MEI Pharma located?

MEI Pharma is headquartered in San Diego, California.

What is ME-401 used for?

ME-401 is an oral inhibitor being developed for recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma.

Stock MEIP logo
MEI Pharma, Inc.

Nasdaq:MEIP

MEIP Rankings

#5391 Ranked by Market Cap
N/A Ranked by Dividends

MEIP Stock Data

16.33M
6.58M
1.31%
41.04%
1.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO